Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
There's no injection, which deters a lot of people
GLP-1 receptor agonists delay gastric emptying and can reduce GI motility , which helps regulate postprandial glucose levels and promotes satiety
Tirzepatide is a dual action GLP-1 and GIP receptor agonist
doi: 10.1053/j.gastro.2016.02.028 6 BaumgartnerM.LangM.HolleyH.CrepazD.HausmannB.PjevacP.et al
Estado clnico ECA en humanos | Observacional | Animal | In vitro Estudiado principalmente en contextos de investigacin neurofisiolgica preclnica y exploratoria, con ensayos humanos controlados limitados
Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability
US$ 23.02
US$ 23.25
US$ 26.23
US$ 29.82
US$ 23.08
US$ 21.30
